| Migraine Disorders
Nurtec ODT vs Qulipta
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Nurtec Odt vs Qulipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQulipta has a higher rate of injection site reactions vs Nurtec Odt based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qulipta but not Nurtec Odt, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nurtec Odt
Qulipta
At A Glance
Oral
As needed or every other day
CGRP receptor antagonist
Oral
Daily
CGRP receptor antagonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 75 mg orally as needed; maximum 75 mg per 24-hour period; safety of more than 18 doses in a 30-day period has not been established; may be taken with or without food.
Episodic migraine 75 mg orally every other day, with or without food.
Migraine Disorders (episodic) 10 mg, 30 mg, or 60 mg taken once daily orally, with or without food.
Migraine Disorders (chronic) 60 mg taken once daily orally, with or without food.
Contraindications
- History of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components, including anaphylaxis and delayed serious hypersensitivity
- History of hypersensitivity to atogepant or any of the components of QULIPTA (reactions have included anaphylaxis and dyspnea)
Adverse Reactions
Most common Nausea, abdominal pain/dyspepsia
Serious Hypersensitivity including dyspnea and severe rash
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Most common (>=4%) Nausea, constipation, fatigue/somnolence
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema), hypertension, Raynaud's phenomenon
Pharmacology
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it is an orally administered small molecule that blocks the CGRP receptor implicated in migraine pathophysiology, indicated for both acute and preventive treatment.
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology and is indicated for preventive treatment of migraine in adults.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nurtec Odt
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (12/12)
Qulipta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Nurtec Odt
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Qulipta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Nurtec Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Qulipta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nurtec OdtView full Nurtec Odt profile
QuliptaView full Qulipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.